Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

DXCM · Q3 2025 Earnings

Dexcom

Reported October 30, 2025

30-second summary

Dexcom posted Q3 FY2025 revenue of $1.209B (+22% YoY, 20% organic) and raised the FY revenue range to $4.630–$4.650B, yet simultaneously cut FY non-GAAP gross margin guidance to ~61% (from ~62%) and widened operating margin to 20–21% (from ~21%). The Q3 print itself was clean — 61.3% gross margin, 22.6% operating margin, $368M EBITDA — but management's own framing acknowledges G7 quality issues impaired new-patient starts and that scrap/freight headwinds persist into Q4. The story isn't the revenue raise; it's that the margin framework promised one quarter ago has been walked back without fanfare.

Headline numbers

EPS

Q3 FY2025

$0.61

Revenue

Q3 FY2025

$1.21B

+22.0% YoY

Gross margin

Q3 FY2025

60.5%

Operating margin

Q3 FY2025

20.1%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$1.21B	+22.0%	$1.16B	+4.5%
EPS	$0.61	—	$0.48	+27.1%
Gross margin	60.5%	—	59.5%	+100bps
Operating margin	20.1%	—	18.4%	+170bps

Guidance

Revenue raised but profitability guidance cut; company raises FY2025 top-line to $4.63–$4.65B (15% growth) while lowering gross and operating margin targets by 50–100 bps, signaling near-term margin headwinds.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2025	$4.600–$4.625 billion	$4.630–$4.650 billion	+$0.005–$0.025 billion at midpoint	Raised
Non-GAAP Gross Profit Margin	FY2025	approximately 62%	approximately 61%	-100 bps	Lowered
Non-GAAP Operating Margin	FY2025	approximately 21%	approximately 20-21%	-50–100 bps at guidance low end	Lowered

Reaffirmed unchanged this quarter: Adjusted EBITDA Margin (approximately 29-30%)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Sensor and Other Revenue	$1.175B	+23.0%
Hardware Revenue	$0.034B	-19.0%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
U.S. Revenue	$0.852B	+21.0%
International Revenue	$0.357B	+22.0%
Non-GAAP Gross Profit Margin	61.3%	—
Non-GAAP Operating Margin	22.6%	—
Adjusted EBITDA	$368.4 million	—
Adjusted EBITDA Margin	30.5%	—
Stelo 12-Month Revenue	>$100 million	—
Cash and Marketable Securities	$3.32 billion	—
Organic Revenue Growth	20%	—
International Organic Revenue Growth	18%	—

Management tone

Q2 FY2025: Supply unlocked, offensive posture → Q3 FY2025: Quality defense, margin walk-back, 2026 guardrail.

Product quality has moved from a non-topic to the opening message. One quarter ago, the prepared remarks led with supply normalization and the incoming-CEO offensive tone. This quarter, management opened with a customer-first reset: "The customer is and will always be the North Star for this company" and "If any of you have an experience with Dexcom that does not meet your expectations, we understand, and that is not good enough for us." The shift signals that G7 quality complaints — which management now concedes had "a bit of an impact on new starts here over the course of the third quarter" — have escalated from a routine remediation issue to a stakeholder-facing reputational risk.

The margin framework promised in Q2 has been quietly dismantled. Last quarter management committed to ~62% gross / ~21% operating / ~30% EBITDA for the full year; this quarter all three have been cut or widened with downside, while the revenue raise gets the headline. The anchor: "our third quarter gross margin was impacted by scrap rates... higher than expected... We expect these scrap rates to continue to improve in the coming months." This is the second consecutive quarter where margin progression has lagged the framework, and the explicit cut — rather than another "improving" narrative — suggests the prior guide was untenable. The hidden cut is the operating margin range: introducing a 20% floor where there was a 21% point estimate creates several hundred million dollars of FY operating-income downside that the revenue raise does not offset.

The 2026 setup is being pre-managed downward. Q2's tone treated 2026 as a continuation of accelerating momentum with Type 2 NIT coverage as inevitable. This quarter management explicitly told investors "the top end of that range probably comes in just under where the street is" on 2026 and that the base case "includes the coverage that we have today" — i.e., assumes no incremental Type 2 NIT wins. That is a deliberate Street reset, not a forecasting accident.

Type 2 NIT coverage has shifted from "imminent" to "when, not if." Last quarter the framing was reimbursement-established with the three largest commercial PBMs and a 25M-person TAM front and center. This quarter the language softened to "it's not if, it's just when" — language that explicitly defers the timing to outside the 2026 base case. The TAM is unchanged; the monetization timeline has elongated.

G7 transition is no longer described as complete. Management acknowledged "some customers reverting to G6" and that the G7 transition is "slower than desired." Q2 framed G7 as the platform; Q3 frames it as a platform that still requires field remediation, which connects directly to the gross margin scrap/freight headwinds.

Recurring themes management leaned on this quarter:

Type 2 diabetes coverage expansion as long-term growth driverG7 quality remediation and customer experience investments15-day sensor launch as future margin and penetration upsideGross margin pressure from scrap and expedited freight near-term headwind2026 growth guidance deliberately conservative vs. Street consensusStello and DexBasil as new product adjacencies targeting broader metabolic health

Risks management surfaced:

Scrap rates and deployment issues persisting into Q4 despite improvementsCustomer perception of G7 quality potentially impacting new starts and prescriber confidenceCompetitive pressure from Abbott dual-analyte platformTiming and scope of Type 2 NIT coverage expansion remains uncertainTransition from G6 to G7 slower than desired; some customers reverting to G6

Answers to last quarter's watch list

Gross margin trajectory — Q3 non-GAAP gross margin was 61.3%, above Q2's 60.1% but below the ~62% bar set last quarter. More importantly, management cut the FY framework to ~61% rather than defend the 62% target, confirming the yellow flag. Scrap rates and expedited freight remain headwinds into Q4. Status: Resolved negatively.

G7 15-Day System launch timing and pricing — No specific launch date or pricing detail was disclosed in the press release. The 15-day sensor remains a forward catalyst per management's themes but the timing question is unanswered. Status: Continue monitoring.

Type 2 non-insulin attach rate evidence — Sensor & Other revenue grew +23% YoY in Q3, an acceleration from +18% in Q2, which is consistent with Type 2 NIT contributing — but management did not break out new-patient mix attributable to Type 2 NIT, and the 2026 base case explicitly excludes incremental coverage wins. The acceleration is real; the attribution is not isolated. Status: Continue monitoring.

CMS competitive bidding proposal milestones — Not addressed in the press release; no rulemaking-calendar update disclosed. Status: Continue monitoring.

Pump-integration competitive response — Not addressed in the press release; management's themes referenced Abbott's dual-analyte platform as a competitive pressure but did not provide installed-base churn or U.S. new-patient share data. Status: Continue monitoring.

What to watch into next quarter

Q4 gross margin print — to hit the revised ~61% FY target, Q4 non-GAAP gross margin needs to print at or above ~62%; a print below 61% would mean two consecutive guide cuts in two quarters and call the 2026 margin trajectory into question.

Formal 2026 guidance vs. the "just under Street" guardrail — Watch the revenue range against the pre-set ceiling. A 2026 revenue guide whose midpoint implies <13% growth would confirm the deceleration narrative; a guide above 14% would signal the guardrail was conservative posturing.

G7 quality KPIs and scrap rate disclosure — Management committed to scrap rate improvement "in the coming months." Watch for any quantification of scrap impact in basis points and whether expedited freight rolls off in Q4 as implied.

Type 2 NIT coverage announcements — Management explicitly excluded incremental wins from the 2026 base case. Any new commercial or Medicare coverage announcement before Q4 print would be pure upside vs. the reset bar.

Stelo run-rate progression past $100M — Now disclosed as a discrete revenue line; watch whether it sustains a doubling trajectory or plateaus, which will determine whether the consumer adjacency is a real growth engine or a small-tail monetization tool.

Sources

Dexcom Q3 2025 press release (Exhibit 99.1), filed with SEC: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000278/dxcm09302025-exhibit991.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.